Oryzon Gets EMA Nod to Test Vafidemstat in Phelan-McDermid Syndrome
Event summary
- EMA approved Oryzon’s Phase II HOPE-2 study for vafidemstat in Phelan-McDermid Syndrome (PMS).
- Study will enroll 12 adult PMS patients, focusing on safety, anger/aggression reduction, and overall disease efficacy.
- HOPE-2 is partially funded through Oryzon’s VANDAM project under Med4Cure, an IPCEI on Health.
- Vafidemstat is the only LSD1 inhibitor in clinical development for CNS disorders.
The big picture
Oryzon’s EMA approval for the HOPE-2 study positions vafidemstat as a potential first-in-class treatment for Phelan-McDermid Syndrome, a rare neurodevelopmental disorder with no approved therapies. The study’s success could validate Oryzon’s epigenetic modulation approach in genetically defined CNS patient populations, potentially unlocking broader applications in other neurodevelopmental syndromes. The partial funding through Med4Cure underscores the strategic importance of this project within the EU’s health innovation framework.
What we're watching
- Clinical Efficacy
- Whether vafidemstat can demonstrate meaningful improvements in aggression and overall disease severity in PMS patients.
- Regulatory Pathway
- The pace at which Oryzon can advance vafidemstat through subsequent clinical phases given the orphan disease designation potential.
- Competitive Positioning
- How Oryzon’s LSD1 inhibitor strategy differentiates it in the crowded CNS epigenetic drug space.
